Innate Pharma Showcases Abstracts Chosen for ASCO 2024 Annual Meeting

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) recently announced that five of their research abstracts have been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, set to take place from May 31 to June 4 in Chicago, Illinois. These abstracts highlight the promising clinical activities of their drug candidates, marking significant advancements in the treatment of various cancers.

Key Highlights from the Accepted Abstracts:

Lacutamab in Mycosis Fungoides:
- Abstract Number: 7082
- Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK Phase 2 trial
- First Author: Pierluigi Porcu
- Session Details: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia, scheduled for June 3, 2024, from 9:00 AM to 12:00 PM.

The TELLOMAK Phase 2 trial focused on lacutamab, demonstrating encouraging clinical activity in patients with relapsed and/or refractory mycosis fungoides, a type of cutaneous T-cell lymphoma. The findings suggest lacutamab's potential as a viable treatment option for this challenging condition.

IPH6501 in CD20-Expressing Non-Hodgkin Lymphoma:
- Abstract Number: TPS7095
- Title: A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
- First Author: Lorenzo Falchi
- Session Details: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia, scheduled for June 3, 2024, from 9:00 AM to 12:00 PM.

- Abstract Number: 7030
- Title: Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL, in comparison to a CD20-targeting T Cell Engager
- First Author: Olivier Demaria
- Session Details: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia, scheduled for June 3, 2024, from 9:00 AM to 12:00 PM.

IPH6501, Innate’s second-generation ANKET® (Antibody-based NK cell Engager Therapeutics), showed promising results in preclinical and early clinical trials for relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma. These studies highlight its safety, tolerability, and antineoplastic activity, positioning IPH6501 as a potential breakthrough therapy in this field.

Monalizumab in Non-Small Cell Lung Cancer:**
- Abstract Number: 8046
- Title: Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)
- First Author: Charu Aggarwal
- Session Details: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers, scheduled for June 3, 2024, from 1:30 PM to 4:30 PM.

- Abstract Number: TPS8129
- Title: A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.
- First Author: Hirva Mamdani
- Session Details: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers, scheduled for June 3, 2024, from 1:30 PM to 4:30 PM.

Monalizumab, developed in collaboration with AstraZeneca, is being tested in Phase 2 trials for its efficacy in treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The abstracts include updated results from the COAST study and a new phase II trial for extensive-stage small cell lung cancer, highlighting the potential of monalizumab in combination therapies.

About Innate Pharma:
Innate Pharma is a leading biotechnology company specializing in immunotherapies for cancer. Their innovative approach leverages the innate immune system through therapeutic antibodies and ANKET® multi-specific NK cell engagers. The company's portfolio includes lacutamab for advanced cutaneous and peripheral T cell lymphomas, monalizumab for lung cancer, and several NK cell engagers targeting various tumor types.

Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and prominent research institutions to drive innovation in cancer treatment. The company, headquartered in Marseille, France, also maintains an office in Rockville, Maryland, and is publicly listed on Euronext Paris and Nasdaq in the US.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!